ArticleBritish journal of cancer2011
A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels.
Article in British journal of cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 70 citations in OpenAlex.
- Targeted drug conjugates and molecular mechanisms in overcoming lung cancer drug resistance.Discover oncology · 2025Review
- Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors.Antibody therapeutics · 2025Review
- Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma.Expert opinion on biological therapy · 2021Review
- Vascular targeted photodynamic therapy: A review of the efforts towards molecular targeting of tumor vasculature.Journal of porphyrins and phthalocyanines · 2019Article
- Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC).Cancers · 2019Review
- Co-administration of Shexiang Baoxin Pill and Chemotherapy Drugs Potentiated Cancer Therapy by Vascular-Promoting Strategy.Frontiers in pharmacology · 2019Article
- The Analysis of Key Factors Related to ADCs Structural Design.Frontiers in pharmacology · 2019Review
- Using antibody directed phototherapy to target oesophageal adenocarcinoma with heterogeneous HER2 expression.Oncotarget · 2018Article
- Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours?Antibodies (Basel, Switzerland) · 2018Review
- Upregulation of the alternative splicing factor NOVA2 in colorectal cancer vasculature.OncoTargets and therapy · 2018Article
- Fibronectins containing extradomain A or B enhance osteoblast differentiation via distinct integrins.The Journal of biological chemistry · 2017Article
- Article
- Porphyrin-based cationic amphiphilic photosensitisers as potential anticancer, antimicrobial and immunosuppressive agents.Biophysical reviews · 2017Review
- In vivo phage display screening for tumor vascular targets in glioblastoma identifies a llama nanobody against dynactin-1-p150Glued.Oncotarget · 2016Article
- F8-SIP mediated targeted photodynamic therapy leads to microvascular dysfunction and reduced glioma growth.Journal of neuro-oncology · 2016Article
- Review
- A specific photoimmunotheranostics agent to detect and eliminate skin cancer cells expressing EGFR.Journal of cancer research and clinical oncology · 2016Article
- Glutamate dependent NMDA receptor 2D is a novel angiogenic tumour endothelial marker in colorectal cancer.Oncotarget · 2016Article
- Antibody-drug conjugates--an emerging class of cancer treatment.British journal of cancer · 2016Review
- Mechanisms of growth inhibition of primary prostate epithelial cells following gamma irradiation or photodynamic therapy include senescence, necrosis, and autophagy, but not apoptosis.Cancer medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe possibility of eradicating cancer by selective destruction of tumour blood vessels may represent an attractive therapeutic avenue, but most pharmaceutical agents investigated so far did not achieve complete cures and are not completely specific. Antibody conjugates now allow us to evaluate the impact of selective vascular shutdown on tumour viability and to study mechanisms of action.
methodsWe synthesised a novel porphyrin-based photosensitiser suitable for conjugation to antibodies and assessed anticancer properties of its conjugate with L19, a clinical-stage human monoclonal antibody specific to the alternatively spliced EDB domain of fibronectin, a marker of tumour angiogenesis.
resultsHere we show in two mouse model of cancer (F9 and A431) that L19 is capable of highly selective in vivo localisation around tumour blood vessels and that its conjugate with a photosensitiser allows selective disruption of tumour vasculature upon irradiation, leading to complete and long-lasting cancer eradication. Furthermore, depletion experiments revealed that natural killer cells are essential for the induction of long-lasting complete responses.
conclusionsThese results reinforce the concept that vascular shutdown can induce a curative avalanche of tumour cell death. Immuno-photodynamic therapy may be particularly indicated for squamous cell carcinoma of the skin, which we show to be strongly positive for markers of angiogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.